Hormone therapy for patients with advanced or recurrent endometrial cancer.
The "gold standard" treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15-20% and nearly ≤ 10%, respectively. This review is focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent endometrial cancers.
Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC; Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan, ROC; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC.
Wen-Ling
WL
Lee
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Ming-Shyen
MS
Yen
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Kuan-Chong
KC
Chao
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan, ROC.
Chiou-Chung
CC
Yuan
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei City Hospital, Taipei, Taiwan, ROC; Foundation of Gynecological Cancer, Taipei, Taiwan, ROC.
Heung-Tat
HT
Ng
Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Hsiang-Tai
HT
Chao
Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC.
Fa-Kung
FK
Lee
Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; Foundation of Gynecological Cancer, Taipei, Taiwan, ROC; Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, ROC. Electronic address: phwang@vghtpe.gov.tw.
Peng-Hui
PH
Wang
D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D009367:Neoplasm Staging; D011372:Progestins / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
D011372:Progestins; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate
advanced endometrial cancer; estrogen; hormone therapy; progesterone; recurrent endometrial cancer